Successful Alzheimer’s Data Would Have Placed Roche At Two-Year Competitive Advantage
Before the markets opened on Monday, Roche Holdings AG (OTC:RHHBY) reported disappointing topline results from the Phase III GRADUATE-1 & 2 of…
FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer
The FDA granted accelerated approval for ImmunoGen Inc’s (NASDAQ:IMGN) Elahere (mirvetuximab soravtansine-gynx) for folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube,…
Roche’s Alzheimer’s Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
Earlier today, MorphoSys AG (NASDAQ:MOR) and its partner Roche Holdings AG (OTC:RHHBY) reported disappointing results from gantenerumab studies in mild cognitive impairment (MCI) due…
Roche’s Another Alzheimer’s Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months
MorphoSys AG’s (NASDAQ:MOR) partner Roche Holdings AG (OTC:RHHBY) announced results from the GRADUATE I and II studies evaluating gantenerumab in mild cognitive impairment…
15 Global Psychedelics Executives To Keep An Eye On In 2022
As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list of some of the top executives in the space to keep an eye on.
Analyst Bullish On SQZ Biotech’s Technology For Solving Cell Therapy Challenges
HC Wainwright initiated coverage on SQZ Biotechnologies Company (NYSE:SQZ) with a Buy rating and a price target of $10. SQZ is focused…
Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts
Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's.
Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests
Roche Holdings AG (OTC:RHHBY) has announced the launch of its next-generation portfolio of COVID-19 rapid antigen tests (2.0) for self-testing and…
Despite Advancement, Benefits From Alzheimer’s Drugs May Be Limited, Say Researchers
Recently, Biogen Inc (NASDAQ:BIIB) and Eisai Co (OTC: ESALY) announced encouraging data from the most-watched Alzheimer’s therapies in the clinic. Lecanemab cleared accumulations…
2 Sympathy Plays To Watch For In The Wake Of Biogen’s Positive Alzheimer’s Drug Data
Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd.